Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Breast Cancer Therapeutics Market size expected to surpass USD 16 billion by 2023

Global Market Insights Inc.
Posted on: 17 Oct 16
Breast Cancer Therapeutics Market size expected to surpass USD 16 billion by 2023

Breast Cancer Therapeutics Market size was valued at over USD 7.5 billion in 2015 and is expected to witness growth to surpass USD 16 billion by 2023.

China breast cancer therapeutics market share accounted for over 15% of the Asia Pacific revenue. Australia accounted for over 10% and India contributed 3% to overall revenue generation, with the latter expected to grow at 9% CAGR over the forecast timeframe. 

According to WHO statistics, it is the second most prevalent type of the disease globally, and the most widespread type in females. In women, it accounts for 20% of all invasive and 13% of all female cancers, and is responsible for 15% of all deaths caused by the disease globally, including both females and males. Every year, around 200,000 new cases in women and nearly 2,000 new cases in men are diagnosed.

This disease occurs when cells in the breast show uncontrolled growth. Malignant tumors may metastatize or growing into the surrounding tissues. It generally either begins in the lobules, which are the milk producing glands, or the inner lining of ducts, the passage that supply milk from lobules. Tumor occurring in the lobules is lobular carcinoma which represents 80% to 90% of all cases, while one which develops from the ducts is ductal carcinoma, representing 10% to 20% of all cases.

Request for a table of content of this report -

In developed countries, the rates are much higher compared to their developing counterparts. However, in many developing nations, it is now rising abruptly due to changes in lifestyle, reproductive factors, and increased life expectancy. Mortality from breast cancer is a leading cause of death among women in developing countries, as well as in the developed world. Approximately 85% to 90% of all cases are caused by genetic abnormality, while the remaining are due to inherited abnormalities. 

High degree of competition, potential side effects, growing number of medication options, and substitute branded drugs availability may adversely impact revenue in the coming years. On the basis of drug class, the industry is categorized into five major segments, namely, anti-metabolites, HER2 inhibitors, aromatase inhibitors, mitotic inhibitors, and hormone receptors. 

Based on the clinical study, the breast cancer therapeutics market can be segmented into Phase I, Phase II, and Phase III drugs. Of these, Phase III drugs are BKM120, Palbociclib (PD-0332991) + Exemestane, Neratinib, DOXIL, ABP 980, NKTR-102, NK105, CT-P6, and Olaparib. Neratinib (developed by Puma Biotechnology), a clinical trial phase IIIdrug, will generate maximum revenue by 2023. It is highly powerful as an irreversible tyrosine kinase inhibitor (TKI).

Pfizer’s palbociclib with fulvestrant contributed considerably to global breast cancer therapeutics market size. In 2015, the company announced that the U.S. Food and Drug Administration (FDA) approved the use of Ibrance (palbociclib). In February 2015, Ibrance was approved and indicated for the treatment of HER2-, HR+ metastatic or advanced breast cancer in amalgamation with letrozole as initial endocrine-based therapy done in postmenopausal women. Ibrance is the only cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the FDA which benefits patients as a first line therapy (along with letrozole). 

Available products comprise a wide range of treatment options, including hormonal, combination, targeted and chemotherapies. Chemotherapy remains the most important class of drugs for treatment; however, the trend of using targeted drugs is on the rise. Treatment for the disease has been modernized in the past decades with increasing usage of targeted therapies. Perpendicular rise in the occurrence of disease makes it an industry where novel molecules and therapies are imperative. Industry novel products include Halaven, a chemotherapeutic agent; Kadcyla, a human antibody-drug conjugate, and Perjeta, a targeted therapy. 

Key players in the breast cancer therapeutics market include AstraZeneca, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis International AG, Pfizer, Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries. Genentech contributed over 60% to the overall breast cancer therapeutics market share in 2015.

Editor's Details

Juee Kate

Last updated on: 17/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.